Goldman Sachs says Valeant has long road ahead, cuts rating
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
Go back to Goldman Sachs says Valeant has long road ahead, cuts rating
November 3, 2015 8:14 AM EST
Beaten down Valeant Pharma (NYSE: VRX) is adding to yesterday's gains in pre-open trade. Shares are up 5.8% to $106.28 after rising 7.15% yesterday. Shares have been under extreme pressure as short sellers point to fraud at the company and regulators point to 'price... More
November 2, 2015 9:27 PM EST
Bill Ackman's Pershing Square Holdings, Ltd. released its regular monthly Net Asset Value (NAV) and Performance Report for the month of October 2015. Data showed the fund was down 7.3% during the month and is now down 19% on the year.
Much of the weakness is tied to the hedge fund's oversized... More
November 2, 2015 3:17 PM EST
Citron Research founder Andrew Left's decision to step back from publishing incremental negative research on Valeant (NYSE: VRX) does absolutely nothing to change the fact that there are things we simply don't know about the company's financials, however it does temporarily remove the threat of death by 1000 tweets. This could open the door for analysts who had been supportive of the company... More
